with cyclophosphamide therapy, we conditionally recommend treatment with methotrexate, azathioprine, or mycophenolate mofetil over rituximab for remission maintenance. Typically, a maintenance agent would be used after remission induction in severe EGPA to reduce toxicity and the risk of disease relapse , although monophasic disease can occur Use of methotrexate, azathioprine, or mycophenolate mofetil is recommended over rituximab, because there has been less experience with the use of